Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.…
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Denali Therapeutics (NASDAQ: DNLI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 503 employees.
The shares were at 18.45 USD on 20 November 2026, up 22.8% over 52 weeks. Its 52-week range is 15.18 USD to 27.30 USD: the price is 32.4% below the high and 21.5% above the low.
Its market capitalisation is 2.96B USD.
Denali Therapeutics reports return on equity of -50.6%.
It holds more cash than debt, a net cash position of 480.95M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 17 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 35.82 USD is 94.2% above the current price. The next earnings report is expected on 25 February 2027.